KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Neogenomics (NEO) over the last 9 years, with Q3 2025 value amounting to $2.1 million.

  • Neogenomics' Current Deferred Revenue rose 11147.21% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 11147.21%. This contributed to the annual value of $745000.0 for FY2024, which is 6502.35% down from last year.
  • Neogenomics' Current Deferred Revenue amounted to $2.1 million in Q3 2025, which was up 11147.21% from $1.5 million recorded in Q2 2025.
  • Neogenomics' 5-year Current Deferred Revenue high stood at $7.6 million for Q4 2022, and its period low was $745000.0 during Q4 2024.
  • Over the past 5 years, Neogenomics' median Current Deferred Revenue value was $4.7 million (recorded in 2021), while the average stood at $4.2 million.
  • As far as peak fluctuations go, Neogenomics' Current Deferred Revenue crashed by 8114.39% in 2024, and later soared by 11147.21% in 2025.
  • Over the past 5 years, Neogenomics' Current Deferred Revenue (Quarter) stood at $6.1 million in 2021, then increased by 24.01% to $7.6 million in 2022, then tumbled by 71.88% to $2.1 million in 2023, then tumbled by 65.02% to $745000.0 in 2024, then skyrocketed by 179.6% to $2.1 million in 2025.
  • Its Current Deferred Revenue was $2.1 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.5 million in Q1 2025.